Related Experiment Video
Updated: May 5, 2026

Collection of Alfalfa Root Exudates to Study the Impact of Di2-ethylhexyl Phthalate on Metabolite Production
Published on: June 2, 2023
Di(2-ethylhexyl) phthalate exposure: Association with metabolic associated steatotic liver disease and underlying
Dapeng Yin1, Yan Li2, Wei Wu1
1Division of Endocrinology, Department of Medicine, The Second hospital of Shanxi Medical University, Taiyuan 030001, China; The Second Clinical Medical College of Shanxi Medical University, Taiyuan 030001, China.
Abstract:
Di(2-ethylhexyl) phthalate (DEHP) is a widely prevalent environmental pollutant that poses a threat to metabolic associated steatotic liver disease (MASLD). However, the specific mechanism remains unclear. This study combined the population data from the National Health and Nutrition Examination Survey (NHANES), and jointly employed network toxicology, molecular docking technology and in vitro cell experiments to establish a multi-dimensional research system of "population-network-molecule-cell". To clarify how DEHP interferes with the MASLD process. Our analysis based on NHANES data showed that DEHP exposure was significantly positively correlated with the risk of MASLD. Network toxicology identified 63 overlapping targets of DEHP and MASLD, and their functions were enriched in lipid metabolism, cytochrome P450-mediated drug metabolism and other pathway levels. Finally, five core targets (AKT1, ESR1, IL10, MMP9, PPARA) were identified. Molecular docking and molecular dynamics simulations indicated that these targets interacted with DEHP. In vitro experiments have shown that DEHP has the potential to induce lipid deposition in hepatocytes and have demonstrated the key role of the core targets. In conclusion, we showed that DEHP was closely related to MASLD through various dimensions. It was revealed that DEHP may regulate the occurrence and development of MASLD through multiple targets and pathways.
More Related Videos
07:12Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
Published on: June 2, 2023
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Pancreatitis II: Pathophysiology
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Cirrhosis II: Pathophysiology